Bio & Pharma
GC Biopharma introduces candidates for treating blood coagulation disease
The company entered into an asset transfer agreement with Catalyst Biosciences to introduce drug candidates for a rare blood coagulation disease
By Mar 02, 2023 (Gmt+09:00)
1
Min read
Most Read
NPS to cut global stocks under GP management, up its direct control
S.Korea's LS Materials set to boost earnings ahead of IPO process
Korean PE funds shrink in 2023 for first time in 7 years
AI to drive Mirae Asset's next-phase growth: chairman
Galaxy Ring, new foldables set to steal the show at Samsung Unpacked Paris
South Korea's GC Biopharma Corp. announced on Tuesday that it had entered into an agreement to transfer assets with Catalyst Biosciences, a US-based drug development firm, in order to introduce drug candidates for a rare blood coagulation disease.
The Korean drug maker will acquire a total of three candidates, including MarzAA, which is currently in the global phase 3 clinical trials. GC Biopharma claims that MarzAA has demonstrated effectiveness and safety in previous clinical trials and is being developed as a subcutaneous injection formulation.
The company intends to continue conducting clinical trials on the candidate substances with the aim of launching a new drug. Previously, GC Biopharma successfully developed Green Mono and Greengene F for hemophilia, one of the blood clotting disorders.
"We will expand our efforts globally to improve the treatment options for patients suffering from various rare diseases, including rare blood clotting disorders," said Huh Eun-chul, CEO of GC Biopharma.
Write to Jae-Young Han at jyhan@hankyung.com
More to Read
-
Bio & PharmaGC Biopharma gets WHO pre-qualification approval for chickenpox vaccine
Feb 21, 2023 (Gmt+09:00)
2 Min read -
Bio & PharmaGC Biopharma's Sanfilippo treatment eligible for FDA priority review
Jan 18, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaGC Biopharma's Ochang facility gets WHO PQ certification
Feb 10, 2023 (Gmt+09:00)
1 Min read
Comment 0
LOG IN